Penehyclidine hydrochloride: A potential drug for treating COPD by attenuating toll-like receptors

Drug Design, Development and Therapy

Volumn 6, Issue , 2012, Pages 317-322

  Xiao, Hong Tao ^a   Liao, Zhi ^b   Tong, Rong Sheng ^a  

^a Department of Pharmacy ^*  (China)

^b SICHUAN PROVINCIAL PEOPLE'S HOSPITAL   (China)

Author keywords

Chronic obstructive pulmonary disease; Penehyclidine hydrochloride; Toll like receptors

Indexed keywords

CHOLINERGIC RECEPTOR BLOCKING AGENT; MUSCARINIC M2 RECEPTOR; MUSCARINIC M3 RECEPTOR; MYELOID DIFFERENTIATION FACTOR 88; PENEHYCLIDINE; TOLL LIKE RECEPTOR; TOLL LIKE RECEPTOR 3; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR ADAPTOR MOLECULE 1; UNCLASSIFIED DRUG;

ANTIINFLAMMATORY ACTIVITY; BRONCHODILATING ACTIVITY; BRONCHUS HYPERREACTIVITY; CARDIOVASCULAR DISEASE; CHRONIC INFLAMMATION; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL FEATURE; DISEASE SEVERITY; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; EPITHELIUM CELL; HUMAN; LUNG ALVEOLUS MACROPHAGE; NONHUMAN; REVIEW; RISK FACTOR; SYSTEMATIC REVIEW;

CHOLINERGIC ANTAGONISTS; HUMANS; MYELOID DIFFERENTIATION FACTOR 88; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; QUINUCLIDINES; TOLL-LIKE RECEPTORS;

EID: 84872289657     PISSN: 11778881     EISSN: None     Source Type: Journal    
DOI: 10.2147/DDDT.S36555     Document Type: Review

References (33)

1. Han X Y, Liu H, Liu CH, et al. Synthesis of the optical isomers of a new anticholinergic drug, penehyclidine hydrochloride (8018). Bioorg Med Chem Lett. 2005;15:1979-1982.
2. Wang YA, Zhou WX, Li JX, et al. Anticonvulsant effects of phencynonate hydrochloride and other anti-cholinergic drugs in soman poisoning neurochemical mechanisms. Life Sci. 2005;78: 210-223.
3. Xiao HT, Liao Z, Mo ZJ. Progress in pharmacokinetics of penehyclidine hydrochloride. Chin J New Drugs. 2009;18:887-890.
4. Chen XZ. Penehyclidine hydrochloride. Cent S Pharm. 2003;1: 188-189.
5. Ma TF, Rong J, Jing Z, et al. Protective effects of penehyclidine hydrochloride on transient forebrain ischemia reperfusion injury in gerbils. Chin J Clin Pharmacol Ther. 2006;11:453-457.
6. Cao FS, Huang JH, Tao ZX, et al. Effects of penehyclidine hydrochloride on the expression of nuclear factor-κB in rats after acute global cerebral ischemia/reperfusion. Ling Nan J Emerg Med. 2006;11:7-9.
7. Qiao JZ, Yang SL, Zhen ZJ, et al. Study on pharmacokinetics of penehyclidine hydrochloride in mice. Chin Pharm. 2003;38:942-944.
8. Gross NJ. Anticholinergic agents in asthma and COPD. Eur J Pharmacol. 2006;533:36-39.
9. Rabe K F, Hurd S, Anzueto A, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med. 2007;176: 532-555.
10. Akira S. Toll-like receptors and innate immunity. Adv Immunol. 2001; 78:1-56.
11. Underhill DM, Ozinsky A. Toll-like receptors: key mediators of microbe detection. Curr Opin Immunol. 2002;14:103-110.
12. Takeda K, Kaisho T, Akira S. Toll-like receptors. Annu Rev Immunol. 2003;21:335-376.
13. Sarir H, Henricks PA, van Houwelingen AH, et al. Cells, mediators and Toll-like receptors in COPD. Eur J Pharmacol. 2008;585:346-353.
14. Stowell NC, Seideman J, Raymond HA, et al. Long-term activation of TLR3 by poly (I:C) induces infammation and impairs lung function in mice. Respir Res. 2009;10:43.
15. Racke K, Matthiesen S. The airway cholinergic system: physiology and pharmacology. Pulm Pharmacol Ther. 2004;17:181-198.
16. Struckmann N, Schwering S, Wiegand S, et al. Role of muscarinic receptor subtypes in the constriction of peripheral airways, studies on receptor defcient mice. Mol Pharmacol. 2003;64:1444-1451.
17. Fisher JT, Vincent SG, Gomeza J, et al. Loss of vagally mediated bradycardia and bronchoconstriction in mice lacking M2 or M3 muscarinic acetyl-choline receptors. FASEB J. 2004;18:711-713.
18. Profta M, Bonanno A, Siena L, et al. Acetylcholine mediates the release of IL-8 in human bronchial epithelial cells by a NFkB/ERK-dependent mechanism. Eur J Pharmacol. 2008;582:145-153.
19. Pavlov VA, Tracey KJ. Controlling inflammation: the cholinergic anti-inflammatory pathway. Biochem Soc Trans. 2007;34: 1037-1040.
20. Niu Z, Zhao DL, Liu CG. The effects of a new cholinolytic-8018 and its optical isomers on the central muscarinic and nicotinic receptors. Arch Int Pharmacodyn Ther. 1990;304:64-74.
21. Jacoby DB, Fryer AD. Anticholinergic therapy for airway diseases. Life Sci. 2001;68:2565-2572.
22. Xiao HT, Liu P, Xie J P, et al. Anti-asthmatic effects of penehyclidine hydrochloride aerosol on guinea pig and rabbit. West Chin J Pharmac Sci. 2006;21:358-360.
23. Xiao HT, Liao Z, Meng XM, et al. Effects of the selective muscarinic receptor antagonist penehyclidine hydrochloride on the respiratory tract. Pharmazie. 2009;64:337-341.
24. Alexopoulou L, Holt AC, Medzhitov R, et al. Recognition of double-stranded RNA and activation of NF-κB by Toll-like receptor 3. Nature. 2001;413:732-738.
25. Morishima H, Kajiwara K, Akiyama K, Yanagihara Y. Ligation of toll-like receptor 3 differentially regulates M2 and M3 muscarinic receptor expression and function in human airway smooth muscle cells. Int Arch Allergy Immunol. 2008;145:163-174.
26. Li J, Gan LG, Cao H, et al. Protective mechanisms of penehyclidine hydrochloride in lung injury after CPB in pediatrics. Anesthesiology. 2008;109:A154.
27. Zhang J, Wang YL, Wang C Y, et al. Protective effects of penehyclidine hydrochloride on septic mice and its mechanism. Shock. 2007;28: 727-732.
28. Wu XJ, Xia ZY, Wang LL, et al. Effects of penehyclidine hydrochloride on pulmonary contusion from blunt chest trauma in rats. Injury. 2012;43: 232-236.
29. Tao YJ, Chen JR, Zhu J, et al. The clinical applications of penehyclidine hydrochloride in patients with AECOPD. Chin J Emerg Med. 2006;15: 255-259.
30. Gosens R, Zaagsma J, Meurs H, et al. Muscarinic receptor signaling in the pathophysiology of asthma and COPD. Respir Res. 2006;7:73.
31. Coulson FR, Fryer AD. Muscarinic acetylcholine receptors and airway diseases. Pharmacol Ther. 2003;98:59-69.
32. Koyama S, Sato E, Nomura H, et al. Acetylcholine and substance P stimulate bronchial epithelial cells to release eosinophil chemotactic activity. J Appl Physiol. 1998;84:1528-1534.
33. Sato E, Koyama S, Okubo Y, et al. Acetylcholine stimulates alveolar macrophages to release infammatory cell chemotactic activity. Am J Physiol. 1998;274:L970-L979.